Journal Mobile Options
Table of Contents
Vol. 35, No. 2, 2010
Issue release date: August 2010
Neuroepidemiology 2010;35:93–99

Socioeconomic Trends in Hospitalization for Multiple Sclerosis

Lad S.P. · Chapman C.H. · Vaninetti M. · Steinman L. · Green A. · Boakye M.
aOutcomes Research Laboratory, VA Palo Alto Health Care System, Palo Alto, Calif., Departments of bNeurosurgery and cNeurology, Stanford University School of Medicine, Stanford, Calif., and dDepartment of Neurology, UCSF School of Medicine, San Francisco, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: Multiple sclerosis (MS) is a neurological disorder with a high burden on patient quality of life and medical rehabilitation services. Little is known about the acute hospitalization costs and characteristics. We examined the trends in MS hospitalizations from 1993 to 2006. Methods: The Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project was searched using the ICD-9 code 340 (MS). Diagnostic, treatment and administrative data were analyzed using basic statistical software. Results: A total of 288,454 hospital admissions with the primary diagnosis of MS occurred between 1993 and 2006, an average of 20,604 admissions annually. The percentage admitted from the emergency department (ED) increased from 19.4 to 60.0% during 1993–2006. The mean cost for each inpatient increased from USD 7,965 to 20,076. The percentage of discharges to home health care increased from 8.6 to 14.9%, and the percentage of discharges to nursing homes and rehabilitation services increased from 8.3 to 22.6%. In 2006, Medicaid patients were significantly more likely to be admitted from the ED (p < 0.001). Medicare payers were significantly more likely to be discharged to a nursing home/rehabilitation (p < 0.0001). Conclusion: National health insurance policies have made measurable effects on MS disease management. MS is becoming more expensive to treat acutely, and improved treatment modalities geared toward decreasing acute flare-ups may provide substantial cost savings by reducing ED visits, inpatient hospitalizations and the need for rehabilitation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hauser SL, Goodin DS: Multiple sclerosis and other demyelinating diseases; in Fauci AS, Braunwald E, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, ed 17. New York, McGraw-Hill, 2008, chapt 375.
  2. Olek MJ: Differential diagnosis, clinical features, and prognosis of multiple sclerosis; in Tarsy D (ed): Multiple Sclerosis. Etiology, Diagnosis, and New Treatment Strategies. Totowa, Humana, 2005, pp 15–53.
  3. Sadiq SA: Multiple sclerosis; in Rowland LP, Merritt HH (eds): Merritt’s Neurology, ed 11. Philadelphia, Lippincott Williams & Wilkins, 2005, chapt 134.
  4. Tremlett H, Yinshan Z, Devonshire V: Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14:314–324.
  5. Coles AJ, Compston DA, Selmaj KW, et al: Alemtuzumab vs interferon-β1a in early multiple sclerosis. N Engl J Med 2008;359:1786–1801.
  6. Hartung HP: Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005;252(suppl 3):iii44–iii50.
  7. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419–425.
  8. Green G, Todd J: ‘Restricting choices and limiting independence’: social and economic impact of multiple sclerosis upon households by level of disability. Chronic Illn 2008;4:160–172.
  9. Prescott JD, Factor S, Pill M, Levi GW: Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44–52.
  10. Agency for Healthcare Research and Quality: Calculating nationwide inpatient sample variances. Rockville, Agency for Healthcare Research and Quality, 2002.
  11. Alonso A, Hernan MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129–135.
  12. Cutter G, Yadavalli R, Marrie R-A, et al: Changes in the sex ratio over time in multiple sclerosis. Neurology 2007;68:A162.

    External Resources

  13. Orton SM, Herrera BM, Yee IM, et al: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932–936.
  14. Shabas D, Heffner M: Multiple sclerosis management for low-income minorities. Mult Scler 2005;11:635–640.
  15. Murray PK, Love TE, Dawson NV, Thomas CL, Cebul RD: Rehabilitation services after the implementation of the nursing home prospective payment system: differences related to patient and nursing home characteristics. Med Care 2005;43:1109–1115.
  16. FDA: Updates. FDA Consumer Magazine, September 1996.
  17. Pleis JR, Lethbridge-Çejku M: Summary health statistics for US adults: National Health Interview Survey, 2006. Vital Health Stat 10 2007;235:1–153.
  18. DeFrances CJ, Cullen KA, Kozak LJ: National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2007;165:1–209.
  19. Nuyen J, Schellevis FG, Satariano WA, et al: Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol 2006;59:1274–1284.
  20. Fleming ST, Blake RL Jr: Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994;47:1127–1132.
  21. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008;14:1091–1098.
  22. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861–7864.
  23. Forman JP, Curhan GC, Taylor EN: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008;52:828–832.
  24. Kragt JJ, van Amerongen BM, Killestein J, et al: Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009;15:9–15.
  25. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet 1998;352:709–710.
  26. Fredrikson S, Cheng Q, Jiang GX, Wasserman D: Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003;22:146–152.
  27. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM: Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524–1527.
  28. Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S: Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586–590.
  29. Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R: Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006;66:685–692.
  30. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B: The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915–928.
  31. Pilz G, Wipfler P, Ladurner G, Kraus J: Modern multiple sclerosis treatment: what is approved, what is on the horizon. Drug Discov Today 2008;13:1013–1025.
  32. Weinshenker BG, O’Brien PC, Petterson TM, et al: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886.
  33. DeNavas-Walt C, Proctor BD, Smith J: Income, poverty, and health insurance coverage in the United States: 2006. Washington, US Government Printing Office, 2007.
  34. O’Brien JA, Ward AJ, Patrick AR, Caro J: Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17.
  35. Heffler S, Smith S, Keehan S, Clemens MK, Zezza M, Truffer C: Health spending projections through 2013. Health Aff (Milwood) Suppl Web Exclusives:2004:W4-79-93.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50